Nonhuman glycans can regulate anti-factor VIII antibody formation in mice
Nonhuman glycans can regulate anti-factor VIII antibody formation in mice
复制标题
DOI:
10.1182/blood.2020009210
复制
发表时间:
2022-03-03
期刊:
影响因子:
20.3
通讯作者:
Stowell, Sean R.
中科院分区:
文献类型:
--
作者:
Arthur, Connie M.;Zerra, Patricia E.;Stowell, Sean R.
Recombinant factor VIII (FVIII) products represent a life-saving intervention for patients with hemophilia A. However, patients can develop antibodies against FVIII that prevent its function and directly increase morbidity and mortality. The development of anti-FVIII antibodies varies depending on the type of recombinant product used, with previous studies suggesting that second-generation baby hamster kidney (BHK)-derived FVIII products display greater immunogenicity than do third-generation Chinese hamster ovary (CHO)-derived FVIII products. However, the underlying mechanisms responsible for these differences remain incompletely understood. Our results demonstrate that BHK cells express higher levels of the nonhuman carbohydrate alpha 1-3 galactose (alpha Gal) than do CHO cells, suggesting that alpha Gal incorporation onto FVIII may result in anti-alpha Gal antibody recognition that could positively influence the development of anti-FVIII antibodies. Consistent with this, BHK-derived FVIII exhibits increased levels of alpha Gal, which corresponds to increased reactivity with anti-alpha Gal antibodies. Infusion of BHK-derived, but not CHO-derived, FVIII into alpha Gal-knockout mice, which spontaneously generate anti-alpha Gal antibodies, results in significantly higher anti-FVIII antibody formation, suggesting that the increased levels of alpha Gal on BHK-derived FVIII can influence immunogenicity. These results suggest that posttranslational modifications of recombinant FVIII products with nonhuman carbohydrates may influence the development of anti-FVIII antibodies.